Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Tislelizumab in resectable esophageal squamous cell carcinoma
Esophagus Cancer
DRUG: Tislelizumab
Pathological complete response, Total tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell, 4 weeks after surgery
Major pathological response, Total/moderate tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell, 4 weeks after surgery|Objective Response Rate, Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor, At the end of Cycle 2 (each cycle is 21 days)
Tislelizumab in resectable esophageal squamous cell carcinoma